You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Tolerability

Treatment-Naïve Patients

GEMINI Logo

Significantly Lower Rate of Drug-Related Adverse Events vs DTG + TDF/FTC at 3 years¹

Overall adverse event profiles were comparable at 144-weeks¹

Adapted from Cahn et al, 2020.¹

DTG 50mg + 3TC 300mg used in the GEMINI studies.

AE = Adverse Event

*The relative risk ratio (95% CI) for Dovato vs. DTG + TDF/FTC was 0.76 (0.63, 0.92).¹

4 deaths occurred overall and were considered unrelated to the study drug regimen: 3 deaths in the DTG + 3TC group (acute myocardial infarction, n=1; Burkitt's lymphoma, n=1; coronary artery disease, n=1; 1 death of unknown cause occurred in the DTG + TDF/FTC group.¹

Virologically Suppressed Patients

TANGO Logo
TANGO Logo

Overall Adverse Events Were Comparable Across Both Arms at 96-Weeks²

  • For the majority of patients in the DOVATO arm, the introduction of 2 new antiretrovials may have contributed to the differences in
    drug-related AEs grade 2 to grade 5.
  • For the majority of patients in the DOVATO arm, the introduction of 2 new antiretrovials may have contributed to the differences in drug-related AEs grade 2 to grade 5.

Adapted from van Wyk et al, 2020.²

AE = Adverse Event

*1 participant was excluded for receiving a TDF-containing regimen instead of a TAF-containing regimen.

2 deaths (1 homicide and 1 unknown reason), both unrelated to treatment, occurred in the DOVATO arm²

References:

  1. Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection—3-year results from the GEMINI studies. Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Poster P018.
  2. van Wyk J, Ajana F, Bisshop F, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study). Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Slides O441.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.

Date of preparation: October 2021 PM-IE-DLL-WCNT-200020